Cotización Generation Uranium - GEN

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

0.125

Postura de Compra

0.095

Postura de Venta

0.125

Volume Operado de la Acción

39,306

0.115 Rango del Día 0.13

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

3.075M

Precio Anterior

0.09

Precio de Apertura

0.115

Hora

153

0.09

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

24,596,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-4.11

Beneficio por acción (BPA)

-0.03

turnover

Beneficio neto

-717k

Sector

Gold Ores

Industria

Unit Inv Tr, Closed-end Mgmt

Sitio web

www.generationuranium.com

Sede

Richmond, British Columbia, Can

Fundado

2022

Generation Uranium Inc is listed in the Gold Ores sector of the TSX Venture Exchange with ticker GEN. The last closing price for Generation Uranium was $0.09. Over the last year, Generation Uranium shares have traded in a share price range of $ 0.00 to $ 0.00.

Generation Uranium currently has 24,596,000 shares in issue. The market capitalisation of Generation Uranium is $2.21 million. Generation Uranium has a price to earnings ratio (PE ratio) of -4.11.

Emerging Markets Report: Piece of Cake

ORLANDO, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Today’s featured company is a simple story. It’s a uranium play. For those of you who have dabbled in the markets for any length of time you may...

Genmab Files IND for HuMax-TF-ADC

Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product Patient enrolment in clinical trial expected...

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN...

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune area - pemphigus vulgaris Patient...

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation PBD-based warhead technology 50:50 partnership ...

Teprotumumab Restarts Clinical Development in New Indication

Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct clinical development under a license from Roche...

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market effective today ADR ticker symbol GMXAY...

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of 9.3 months compared to chlorambucil alone No...

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced...

Genmab Announces Financial Results for the First Quarter of 2013

COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net sales increased 65% over Q1...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
SOP.HSoperior Fertilizer Corp	$ 0.01 (100.00%)	1,000
WWTWater Ways Technologies Inc	$ 0.01 (100.00%)	40k
LSTRLodestar Metals Corp	$ 0.03 (50.00%)	3k
SHLL.PShellron Capital Ltd	$ 0.075 (50.00%)	1,000
GBMLGlobal Battery Metals Ltd	$ 0.03 (50.00%)	7.5k
AVCRAvricore Health Inc	$ 0.06 (-57.14%)	3.28M
ETUE2gold Inc	$ 0.005 (-50.00%)	176.81k
MMNMonarca Minerals Inc	$ 0.005 (-50.00%)	36.89k
KLMKermode Resources Ltd	$ 0.005 (-50.00%)	53.5k
AROC.PArgo Opportunity Corp	$ 0.08 (-46.67%)	5.5k
GSVRGuanajuato Silver Company Ltd	$ 0.20 (11.11%)	8.41M
SCZSantacruz Silver Mining Ltd	$ 0.265 (3.92%)	7.52M
CTMCanterra Minerals Corp	$ 0.10 (0.00%)	6.65M
AAGAftermath Silver Ltd	$ 0.51 (7.37%)	4.15M
QNCQuantum Emotion Corp	$ 0.105 (-4.55%)	4.05M